Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Eltrombopag for aplastic anaemia in Europe

Regis Peffault de Latour • 1 Sep 2020
EBMT 2020
Anemias Aplastic Anemia Cyclosporine Eltrombopag Horse antithymocyte globulin
Race

Régis Peffault de Latour, MD, PhD, Saint-Louis Hospital, Paris, France, discusses the Severe Aplastic Anemia Working Party (SAA-WP) guidelines on the use of eltrombopag, in aplastic anemia patients in Europe. Dr de Latour also touches on the RACE trial (NCT02099747), a multicenter study comparing horse antithymocyte globulin and cyclosporine A with or without eltrombopag as front-line therapy for severe aplastic anemia patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Regis Peffault de Latour

2:55
RACE: evaluating eltrombopag in severe aplastic anemia
Regis Peffault de Latour • 3 Sep 2020
1:17
Overview of HSCT and GvHD at EBMT
Regis Peffault de Latour • 3 Sep 2020
2:21
LNP023 for paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour • 2 Sep 2020
1:01
Aplastic anemia: EHA highlights
Regis Peffault de Latour • 15 Jun 2019

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
3:45
A 2-year analysis of the EBMT-SAAWP RACE trial: eltrombopag in aplastic anemia
Antonio Risitano • 16 Apr 2024
1:31
Mitapivat improves work/school attendance in patients with pyruvate kinase deficiency
Hanny Al-Samkari • 9 Dec 2023
2:13
SATISFY: mitapivat in patients with erythrocyte membranopathies
Kevin Kuo • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals